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Background and Objectives. Dendritic cells (DC)
primed with tumor antigens can effectively mediate the
regression of a variety of established solid malignancies
in both murine and human models. Several experimental
studies indicate that apoptotic bodies are an optimal
source of tumor antigens for ex vivo priming of DC. How-
ever, the clinical use of killed tumor cells as a source of
antigens will require an optimal methodology to induce
effective tumor cell apoptosis.
Design and Methods. The goal of this study was to
compare the efficiency of three agents for inducing neo-
plastic B lymphocyte apoptosis; staurosporine, infection
by modified vaccinia (MVA) viral particles and ultraviolet
C (UVC) radiation.
Results. The three methods were finely tuned to induce
apoptosis in more than 90% of tumor cells after 24 hours
of exposure. However, the viability of monocyte-derived
DC, loaded with B-cell tumor apoptotic bodies induced by
staurosporine or MVA viral particles, decreased dramati-
cally within 48 hours after phagocytosis of the killed neo-
plastic cells. The persistence of the apoptosis-inducing
agents in the apoptotic bodies and not in the tumor super-
natant, was responsible for the observed damage to DC
viability. In contrast, DC viability was not affected after
uptake of tumor cells killed through UVC-irradiation. Fur-
thermore, B-lymphoblastic cell line (LCL)-specific T cells
were reactivated by DC loaded with apoptotic bodies
induced by UVC-rays.
Interpretation and Conclusions. Since the method
used to induce tumor cell apoptosis might be detrimen-
tal to DC viability, these findings should be considered
when designing anticancer vaccination programs.
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immunotherapy, non-Hodgkin's lymphoma, apoptosis.
Haematologica 2003; 88:1396-1404
http://www.haematologica.org/2003_12/1396.htm
©2003, Ferrata Storti Foundation
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells
induced by staurosporine or vaccinia virus infection
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Dendritic cells (DC) are considered professional anti-gen-presenting cells (APC) and play a central rolein regulating immune responses.1,2 Recent evidence
indicates that ex vivo generated DC primed with tumor
antigens3 can stimulate the regression of established
renal cell carcinoma4,5 and melanoma.6,7 Several tech-
niques are now available for creating tumor-specific DC
vaccines, such as DC loading with peptides, or killed
tumor cells, or by tumor-associated antigen gene trans-
duction.8-10
Among these strategies, the use of whole tumor cells
as the source of antigens has the advantage of transfer-
ring a wide spectrum of known and unknown antigens,
characterizing the tumor cells in all stages of its devel-
opment and differentiation, to the APC.11 This strategy
should enable vaccine preparations to be obtained even
if the tumor cells are not immunologically well charac-
terized. The additional presence in killed tumor cells of
epitopes for T-helper lymphocytes may be beneficial
since MHC II-restricted T-helper lymphocyte activation
plays a pivotal part in the physiologic immune response
to pathogens and might be of considerable importance
in the tumor rejection process.12,13 On the other hand,
protocols based on immunization against a single tumor
antigen carry a potential risk of inducing escape variants
or being ineffective on heterogeneous tumor cell popu-
lations. Methods that yield a pool of tumor antigens
include tumor lysate generation,14 apoptotic bodies,15
tumor-derived exosomes,16 and tumor-DC fusion.17 The
use of apoptotic bodies of tumor cells seems to be an
appropriate way to assure an adequate cross-presenta-
tion of tumor antigens by DC.7,15 DC take up apoptotic
and necrotic cells by an endocytic pathway allowing the
processing of proteins eventually resulting in peptide
loading of class I and II HLA molecules.18 Several authors
have recently reported that apoptotic tumor cells are
better than cell lysate in promoting cross-priming of
cytotoxic T lymphocytes (CTL) using different human
tumor cell histotypes.19-21
However, to be useful in a clinical setting the method
to induce apoptosis should kill all the neoplastic cells,
thus preventing reinfusion of viable tumor cells into the
patient. In the present study, we compared several meth-
ods for inducing apoptosis of primary leukemia and lym-
phoma cells for subsequent loading on monocyte-derived
DC. In addition, we evaluated DC viability after these
cells had been loaded with apoptotic bodies induced by
vaccinia viral particle infection, staurosporine treatment
or exposure to UVC-ray irradiation.
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Design and Methods
Cell isolation and culture
Immature dendritic cells were generated from
peripheral blood mononuclear cells (PBMC) of
patients with chronic lymphatic leukemia (CLL) or
follicular lymphoma (FL) as described by Sallusto
and Lanzavecchia.22 Briefly, CD14+ cells obtained
from PBMC using an immunomagnetic technique
according to the manufacturer’s instructions (CD14
microbeads kit, Miltenyi Biotec, Bergisch Gladbach,
Germany) were incubated at 37°C in 5% CO2 at a
concentration of 106 cells/mL in 10% FCS (Hy
Clone, Logan, UT, USA), RPMI (Bio Whittaker
Europe, Walkersville, MD, USA), in the presence of
recombinant human interleukin-4 (20 ng/mL;
Schering Plough, Kenilworth, NY, USA) and recom-
binant human granulocyte-macrophage colony-
stimulating factor (50 ng/mL; Molgramostim,
Myelogen, Sandoz). On day +5, adherent and non-
adherent cells were collected, labeled with anti-
CD1a, anti-CD14, anti-CD83 monoclonal antibod-
ies and analyzed by FACScalibur (Becton Dickin-
son, San José, CA, USA).
CD19+ tumor cells harvested from ten peripher-
al blood (PB) and ten bone marrow (BM) samples
from patients with CLL (n=5) and FL (n=5) were
selected using a high-gradient immunomagnetic
technique according to the manufacturer’s instruc-
tions (CD19 microbeads kit, Miltenyi Biotec, Ber-
gisch Gladbach, Germany) and then frozen. Tumor
cell purity in the final preparation was evaluated by
κ/λ light chain analysis (κ/λ simultest, Becton
Dickinson, San José, CA, USA).
A human lymphoblastic cell line (LCL) was gen-
erated and cultured in RPMI with 10% human
serum, as described elsewhere.23 All patients were
informed about the study and gave oral consent to
the procedures.
Tumor antigen preparation
Three different methods to induce apoptosis were
tested: (i) CD19+ tumor cells were infected by mod-
ified Ankara vaccinia virus (MVA, Bavarian Nordic,
Germany) as reported elsewhere.9 Briefly, pelleted
tumor cells were incubated for 2 hrs at 37°C in 5%
CO2 with sonicated MVA viral particles at different
multiplicities of infection (MOI) (from 5 to 500
MOIs). After washing three times, the cells were
incubated at 37°C in 5% CO2 for 24 hrs; (ii) CD19+
tumor cells were incubated at 37°C in 5% CO2 for
16 hrs with a microbial alkaloid, staurosporine (Sig-
ma Chemicals Co., Steinheim, Germany), a strong
inhibitor of protein kinases,24 at different concen-
trations (1, 2.5 and 5 mM). After washing three
times, the cells were incubated at 37°C in 5% CO2
for 24 hrs; (iii) CD19+ tumor cells or LCL were
exposed to a dose of 10 J and 15 J of UVC irradia-
tion from a 9W UVC lamp (T-UV9 UV-C Germicidal
Lamp Philips, Holland) and then incubated at 37°C
and 5% CO2 for 24 hrs. After 24 hrs of incubation,
apoptosis was evaluated by FACScan analysis using
an annexin V-propidium iodide (PI) assay (MedSys-
tems Diagnostics GmbH, Vienna, Austria). We cal-
culated the percentage of apoptotic cells as the
sum of early (annexin V+/PI−) and late apoptotic
cells (annexin V+/PI+).
Tumor antigen uptake by DC
Immature DC were incubated for 48 hrs with
apoptotic tumor cells (1:2 ratio) at a concentration
of 1.5×106 cells/mL. The percentage of DC con-
taining apoptotic bodies was evaluated in two
ways: fluorescent microscopy (FM) and FACScan
analysis. When FM was used, DC and tumor cells
were labeled with two different stains: green CMF-
DA (Molecular Probe, Eugene, Oregon, 1 ng/mL)
and red CMFTR (Molecular Probe, Eugene, Oregon,
5 ng/mL) fluorescent stains, respectively. DC con-
taining apoptotic tumor bodies appeared as yellow
spots, due to the mixture of red and green fluores-
cence signals.
To calculate the exact number of DC which could
take up apoptotic bodies, we used FACscan analy-
sis after labeling DC and tumor cells with red
CMFTR (10 ng/mL) or green CMFDA (1 ng/mL). Try-
pan blue (Sigma Chemicals Co., Steinheim, Ger-
many) was added to quench the green fluorescence
in order to evaluate the apoptotic bodies attached
to the DC surface.25 The trypan blue only entered
the stained cells and stopped the fluorescent emis-
sion if the apoptotic bodies were on live DC. As a
negative control, the same experiments were per-
formed at 4°C to prevent phagocytosis.
DC viability after phagocytosis of apoptotic
tumor cells
In order to evaluate whether apoptotic bodies
might cause toxic damage to DC, the viability of
the DC, after they have been loaded with apoptot-
ic bodies, was tested using propidium iodide stain-
ing (MedSystems Diagnostics GmbH, Vienna, Aus-
tria, 10 µg/mL). Briefly, the DC were labeled with
CMFDA green stain and then incubated for 48 hrs
with apoptotic tumor cells. To rule out that toxic
damage to DC could result from the presence of
staurosporine or MVA viral particles in the super-
natant, DC were also incubated for 48 hours with
the supernatant of neoplastic cells previously
exposed to staurosporine or MVA viral particles.
After both incubations, the DC were extensively
washed and, after staining with propidium iodide
and CD19 PE (Becton Dickinson, San José, CA, USA),
were analyzed by flow-cytometry.
Co-culture of DC with autologous PBMC and
interferon-γg ELISPOT assay
In order to evaluate the cross-priming of tumor
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antigens by DC after phagocytosis of apoptotic bod-
ies, PBMC were activated against an autologous
Epstein-Barr virus (EBV)-induced lymphoblastoid
cell line.26 Immature DC were cultured for 24 hrs
with LCL induced to undergo apoptosis by exposure
to 10 J UVC-irradiation. After extensive washing,
the DC were matured by 12-hr incubation with
tumor necrosis factor (TNF)-α (10 ng/mL) and then
co-cultured with autologous PBMC (ratio 1:4) in
10% heat-inactivated human serum RPMI. During 4
weeks of culture, fresh DC loaded with killed LCL
were added to the culture every 7 days to restimu-
late autologous PBMC. On days +1, +3, +5 of every
week, the cultures were fed with rh-IL2 (Proleukin;
Chiron, Amsterdam, Netherlands, 10 U/mL). The lym-
phocytes activated by DC loaded with UVC-ray-
induced apoptotic autologous LCL were 41.5% CD8+
cells and 58.5% CD4+ cells. Enzyme-linked immu-
nospot (ELISPOT) assays were performed to assess
the interferon γ (IFN-γ) production by lymphocytes
activated by autologous DC loaded with apoptotic
autologous LCL induced by UVC-ray exposure, as
described elsewhere.27 Briefly, wells in 96-well plates
with nitrocellulose membrane (Millipore, Bedford,
MA, USA) were coated with primary anti-INF-γ anti-
body (clone MAB1-D1K; Mabtech, Nacka, Sweden)
diluted in NaHCO3 buffer at pH 9.2 and incubated
at 4°C overnight. To remove the primary antibody in
excess, the plates were washed six times with PBS
containing 0.5% of FBS before seeding the effector
and target cells. The assay was performed in tripli-
cate and responder fourth-week activated T cells
were seeded at 104, 2.5×104 or 5×104 cells/well.
DC loaded with UVC-induced apoptotic LCL were
seeded in a fixed number of 1.67×104 cells/well. As
controls, unloaded DCs, apoptotic or live LCL alone
were cultured with the responders.
After 24 hrs of incubation at 37°C in 5% CO2,
the cells were removed from the plate by washing
six times with PBS supplemented with 0.5% FBS.
A biotinylated secondary anti-INFγ-antibody (clone
Mab7-B6-1; Mabtech) was added for 2 h at room
temperature to each well. After extensive wash-
ing, the plates were incubated for 1 hr at room
temperature with the avidin-alkaline phosphatase
(AP) complex reagent (Mabtech, Sweden). The AP
substrate was added and incubated for 20 minutes
to develop spots. The reaction was stopped under
running tap water. When the plate was complete-
ly dry, the spots were counted by computer-assist-
ed image analysis (AID, Strassberg, Germany).
Results
Apoptosis of leukemia and lymphoma cells
is induced efficiently by several agents
We observed a powerful induction of apoptosis
of CLL and FL cells after treatment with all three
methods investigated (MVA viral particles infec-
tion, staurosporine treatment, and UVC-ray expo-
sure). No significant differences were observed
between the different cell types (CLL or FL cells and
BM or PB cells). As shown in Figure 1, staurosporine
treatment and MVA infection induced apoptosis of
tumor cells in a dose-dependent manner. Using
staurosporine, we observed the highest percentage
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Figure 1. Percentage of apoptotic
neoplastic B lymphocytes. Neoplas-
tic B lymphocytes were: a) incubat-
ed with sonicated MVA viral parti-
cles at different MOI (5, 10, 15,
50,100, 250, 500) for 2 hrs at
37°C; b) incubated with stau-
rosporine at different doses (1, 2.5
and 5 µmM) for 16 hrs; or c) exposed
to UVC irradiation (10 J -15 J). After
three washes, the cells were incu-
bated for 24 hrs before evaluation
of the percentage of early (annexin
V+/propidium iodide−-) and late
(annexin V+/propidium iodide+)
apoptosis by FACScan analysis
using the annexin V-propidium
iodide assay. The results show the
total fraction of apoptosis (early +
late) observed in the different con-
ditions and the data are expressed
as mean ±SD of triplicates of ten
separate experiments.
No treatment
Percentage of apoptotic cells
MVA
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of apoptotic tumor cells (97.8±5.1%) after 24-hr
culture with a dose of 5 µM. Using MVA viral par-
ticles with MOI ranging between 5 and 500, the
apoptotic tumor cell fraction increased to between
21.3±3.9% and 95.8±2.3%, respectively. Moreover,
94.6±1.5% of the tumor cells were rendered apop-
totic using an MOI of only 250. Finally, the per-
centage of apoptotic tumor cells was 96.3±2.3%
after 24-hrs exposure to 10 J UVC-rays. These
results did not change significantly when the UVC
dose was increased to 15 J. Comparable percent-
ages of apoptotic cells were obtained when LCL
were used. Thus, on the basis of these results, we
used staurosporine at 5 µM, MVA infection with an
MOI of 250 and 10 J UVC-ray exposure for the sub-
sequent experiments.
Immature monocyte-derived DC efficiently
take up apoptotic tumor bodies
The uptake of fluorescent latex beads, detected
by FM or FACScan analysis, was used to identify the
maturation state of the DC with the highest phago-
cytic capacity. In all subsequent experiments were
used 5-day cultured monocyte-derived DC since
they were found to have the highest uptake capac-
ity (data not shown).
Flow cytometry and FM analysis were also use to
assess tumor cell uptake by DC. After labeling the
DC with red CMFTR and the apoptotic tumor cells
with green CMFDA stains, the uptake of apoptotic
bodies by DC was documented by flow-cytometry
(Figure 2, Panel A). Furthermore, the addition of
trypan blue to quench the green fluorescence,
before FACScan analysis, enabled us to exclude
that double positive events reflected apoptotic cells
adhering to the DC membrane rather than phago-
cytosed cells (Figure 2, Panel A). As a negative con-
trol, we performed the same experiments at +4°C
to inhibit DC phagocytic activity (Figure 2, Panel B).
Table 1 summarizes the percentage of DC (ranging
from 84% to 96%) that contained killed tumor
cells: the efficiency of DC loading did not differ
significantly according to the method used to
induce tumor cell apoptosis.
DC viability may be reduced after uptake of
apoptotic tumor cells
After intensive washing, apoptotic tumor cells
were co-cultured for 48 hrs with monocyte-derived
DC. As shown in Figure 3, DC viability was dra-
matically reduced when the DC were co-cultured
with apoptotic cells induced by MVA viral infection
or staurosporine treatment. In fact, the dead CMF-
DA+/PI+ labeled DC were 90±5% and 92.7±6%,
respectively. The very low amounts of viable DC
prevented evaluation of their phagocytic or APC
activity. DC cultured for 48 hours with UVC-
induced apoptotic cells were minimally damaged
(only 10±5% of CMFDA+/PI+ DC died). In addition,
the supernatant harvested after exposure of neo-
plastic B cells to staurosporine or MVA viral parti-
cles did not induce DC damage (Table 2).
Reactivation of B-LCL-specific T cells by DC
loaded with UVC-killed B-LCL
In an autologous system, ELISPOT analysis was
used to evaluate the frequency of IFN-γ producing
lymphocytes induced by DC loaded with UVC-
induced apoptotic LCL. The numbers of IFN-γ-pro-
ducing lymphocytes increased after three and four
weeks of stimulation with antigen-pulsed DC, but
not in cultures with unpulsed DC, or in cultures
containing lymphocytes with apoptotic bodies
Table 1. Percentage of DC containing apoptotic bod-
ies.
% of DC containing 
tumor apoptotic bodies
37°C 4°C
Apoptotic without with without with
body trypan trypan trypan trypan 
inducer blue blue blue blue
UVC rays 99±3 96±2 12±2 9±3
(10 J)
MVA 90±3 84±3 10±2 6±3
infection (MOI 250)
Staurosporine 95±6 93±3 14±3 11±2
(5 µM)
Data are expressed as mean ±SD of triplicates of five separate
experiments.
Table 2. Supernatant from MVA-infected or stau-
rosporine-treated neoplastic B cells does not affect
DC viability.
% of dead DC
DC cultured With Without
Supernatant from 10±3 9±3
MVA-infected
tumor cells
(MOI 250)
Supernatant from 15±3 12±3
staurosporine-treated
tumor cells (5 µM)
aPercentage of dead DC after culture for 48 hours with
supernatant from MVA-infected or staurosporine-treated
neoplastic B cells. Data are expressed as mean ±SD of triplicates
of five separate experiments.
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Figure 2. Detection of DC containing UVC-induced apoptotic bodies by flow cytometry and fluorescent microscopy
analysis. DC were stained by CMFTR red while UVC-induced apoptotic cells were labeled with CMFDA green. After
48 h of co-culture with apoptotic bodies, DC were analyzed by flow-cytometry. In the upper part of Panel A, DC
containing apoptotic bodies resulted CMFTR+/CMDA+. The trypan blue dye exclusion test was used to quench
the green florescence and discriminate between ingested apoptotic bodies and those merely adherent to the mem-
brane of DC. The analysis was performed on gated cells derived from typical side and forward scatters of DC. Flu-
orescent microscopy (bottom part of Panel A) was used to confirm the presence of DC containing apoptotic bod-
ies (yellow spots). In Panel B, the same experiment was performed at +4°C to inhibit DC phagocytosis. In this
condition, the apoptotic bodies remained outside the DC and no CMFTR+/CMDA+ DC (upper part of Panel B) or
yellow spots (bottom part of Panel B) were detectable. Data are from one representative experiment out of five.
without
trypan blue
without
trypan blue37°C
4°C
with
trypan blue
with
trypan blue
A
B
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without DC, or lymphocytes alone. As shown in
Figure 4, at the fourth week of stimulation,
133±5/104 lymphocytes activated by pulsed DC
produced INF-γ spots. The number of INF-γ-pro-
ducing lymphocytes after activation by DC loaded
with apoptotic bodies was 7 and 3 times greater
than when apoptotic bodies alone (19.5±2
spots/104 cells; p = 0. 005) or unpulsed DC (46±5
spots/104 cells; p = 0.005) were used as stimulators.
As expected, live LCL were optimal antigen pre-
senting cells, inducing ten times more spots than
did the apoptotic LCL (Figure 4).
Figure 3. DC viability after loading with apoptotic bodies. DC were stained with green CMFDA and, after 48 hrs
of incubation without (Panel A) or with (Panel B, C, D) apoptotic bodies, were labeled with proidium iodide and
analyzed by flow-cytometry. The percentage of CMFDA+/PI+ DC loaded with UVC-induced apoptotic bodies was
negligible (Panel B) whereas the percentage of CMFDA+/PI+ DC loaded with apoptotic bodies induced by 5 µM
staurosporine treatment (Panel c) or by 250 MOI MVA viral infection (Panel D) resulted to be ≥ 90%. The absence
of CD19+/CMFDA+ cells indirectly excluded CD19+ necrotic tumor cells adherent to the DC membrane from the
count. Data are from one representative experiment out of five.
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Discussion
Whole tumor cells, as a source of antigens, may
be an attractive priming strategy for vaccine
approaches since they provide a wide spectrum of
tumor-specific and tumor-associated antigens.15,28
In addition, this approach may in principle counter-
act the ability of neoplastic cells to escape immune
recognition by down modulation of one or more
antigenic determinants. On the other hand, empha-
sis on the clinical applications of this approach is
reduced by uncertainty regarding the optimal means
for treating tumor cell preparations, by the possi-
bility of inducing autoimmunity against self anti-
gens and by the debate regarding the optimal
tumor: DC ratios for effective priming of T cells.29 In
spite of these uncertainties several whole tumor cell
preparation methods have been shown to be effec-
tive for loading DC and then eliciting antitumor
immune responses. Cross-priming of CTL with anti-
tumor activity has been demonstrated with DCs
pulsed with tumor cell lysate30 and apoptotic tumor
cells.21,32-34 Specifically, Schnurr et al.19 demonstrat-
ed that antigens from apoptotic pancreatic carci-
noma cell lines, either in the form of whole cells or
as released particles, were more potent than tumor
lysates in inducing T-cell priming and activation by
DC. In addition, Hoffman et al.21 reported stronger
CTL responses with apoptotic tumor cells than with
cell lysates in a squamous cell carcinoma model.
The enhanced CTL activation by antigens from
apoptotic cells may be attributed to several mech-
anisms. After ingestion, most particulated antigens
requiring phagocytosis are digested into peptides
associating with MHC class-II molecules in the
endocytic compartments and are presented to T-
Figure 4. Activation of INF-γg-producing lymphocytes after culture with DC loaded with LCL apoptotic bodies. DC
loaded with LCL apoptotic bodies induced by UVC-ray exposure were used as stimulators of autologous PBMC.
After 3 and 4 weeks of culture, ELISPOT assays were performed to evaluate the number of INF-γg producing autol-
ogous lymphocytes. At the fourth week, 133±5/104 lymphocytes produced INF-γg spots after activation by DC
pulsed with apoptotic bodies, i.e. 7 times more than was obtained using apoptotic bodies alone (19.5±2 spots/104
cells; p = 0.005) and 3 times more than obtained using unpulsed DCs (46±5 spots/104 cells; p = 0.005). Data
are from one representative experiment out of three.
PBLs (No activation)
PBLs (3 weeks of activation)
PBLs (4 weeks of activation)
no
stimulation
DC alone apoptoticLCL alone
DC loaded
with killed
LCL
PHA live LCL
alone
IF
N
-γg
sp
ot
s/
10
4
T-
ce
lls
250
200
150
100
50
0
                     
DC viability after phagocytosis of NHL apoptotic bodies
haematologica/journal of hematology vol. 88(12):december 2003 1403
helper cells.35 This is believed to be the predominant
cell lysate processing pathway. Conversely, scav-
enger receptor-mediated phagocytosis of apoptot-
ic tumor cells allows antigens to gain access to
MHC class-I compartments, resulting in cross-pre-
sentation of the antigens to CTL.31 In addition,
enhanced CTL responses to tumors might be medi-
ated by heat shock proteins expressed by stress-
induced apoptotic tumor cells.36 On the basis of
this theoretical background and reported observa-
tions,19,21 there is a scientific consensus that anti-
gen preparations from apoptotic tumor cells rep-
resent a promising alternative to tumor lysate in
DC-based tumor vaccines.
Taken together the existing data on preclinical
models strongly suggest that DC loading with killed
tumor cells may be an effective strategy for prim-
ing T-cell-mediated anti-tumor responses.
However, the best method for inducing apopto-
sis of neoplastic cells, with the efficiency required
by a clinical protocol, remains to be assessed. To
this end, we tested three strategies for inducing
apoptosis in B-cell tumors. First, neoplastic B lym-
phocytes were transduced with MVA viral parti-
cles. We chose this agent since viral infection could
even induce CD4+ T helper response against viral
determinants, a response that in principle could
behave as an adjuvant in the antitumor response.
Second, we cultured neoplastic B lymphocytes in
the presence of staurosporine,37 since this drug has
already been successfully used for the treatment of
lymphoproliferative diseases. Finally, neoplastic B
cells were exposed to UVC-rays, a well-known
method for promoting apoptosis.19 By fine tuning
the conditions to induce apoptosis by the three
methods, highly effective tumor killing was
achieved in all instances: less than 1% of the tumor
cells were still alive after 48 hours of exposure to
the different agents. However, we observed toxic
damage of DC after the phagocytosis of apoptotic
bodies whose apoptosis had been induced by stau-
rosporine or MVA viral particles. A significant loss
of DC viability was observed only when we utilized
concentrations of the latter agents which caused
≥ 95% of apoptosis of the tumor cells. Under these
experimental conditions, the percentage of DC still
alive after 48 hrs of co-culture with apoptotic bod-
ies was very low. According to our experiments, it
can be suggested that apoptotic bodies internalized
by DC release viral particles as well as stau-
rosporine which in turn induce toxic damage of
DC. In contrast, the viability and APC function of
the DC were preserved when these cells were
loaded with UVC-induced apoptotic bodies. In fact,
DC loaded with killed autologous B-LCL were able
to activate B-LCL-specific T cells.
In conclusion, we demonstrated that even
though several agents could be used to induce
apoptosis of neoplastic human B lymphocytes, the
persistence of apoptosis inducers inside the apop-
totic bodies affects DC viability. The percentage of
viable DC after loading with apoptotic bodies
induced by MVA infection or staurosporine, at con-
centrations required for clinical purposes, thus
drops to extremely low levels. UVC radiation is con-
sequently the best means for inducing tumor cell
apoptosis for use in a clinical setting, since it had
no observable harmful effect on the viability or APC
function of DC. For these reasons, we are starting
a clinical protocol of vaccination using autologous
monocyte-derived DC loaded with UVC-killed
autologous tumor cells in indolent non-Hodgkin’s
lymphoma patients.
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